PDF(Pubmed)
Abstract：
This study aimed to confirm urinary protein fragments in relation to the presence of pancreatic ductal adenocarcinoma (PDAC) via a C-terminal proteomics strategy using exploratory and validation cohorts. Urinary fragments were examined by iTRAQ-labelling of tryptic peptides and concentrations of C-terminal fragments were evaluated. Only the urinary CD276 fragment showed a fold change (FC) of > 1.5 with a significant difference of P < 0.01 between healthy (H) and PDAC participants in both the exploratory (H, n = 42; PDAC, n = 39) and validation cohorts (H, n = 36; resectable PDAC, n = 28). The sensitivity and specificity of the CD276 fragment for diagnosing resectable PDAC were 75% and 89%, respectively, in the validation cohort. Postoperative urinary levels of the CD276 fragment were low as compared to those before surgery (n = 18, P < 0.01). Comprehensive C-terminus proteomics identified an increase in the urinary CD276 fragment level as a feature of patients with PDAC. The urinary CD276 fragment is a potential biomarker for detecting resectable PDAC.
摘要：
本研究旨在通过C端蛋白质组学策略，使用探索性和验证性队列，确认尿蛋白片段与胰腺导管腺癌（PDAC）的存在有关。通过胰蛋白酶肽的iTRAQ标记检查尿片段,并评估C末端片段的浓度。仅尿CD276片段显示>1.5的倍数变化（FC），健康（H）和PDAC参与者在两个探索性（H，n=42；PDAC，n=39)和验证队列(H，n=36；可切除的PDAC，n=28）。CD276片段诊断可切除PDAC的敏感性和特异性分别为75%和89%,分别,在验证队列中。与手术前相比，术后尿液中CD276片段的水平较低（n=18，P<0.01）。综合C端蛋白质组学鉴定尿CD276片段水平的增加是PDAC患者的特征。尿CD276片段是用于检测可切除的PDAC的潜在生物标志物。
